Nerandomilast slowed lung function decline in people with IPF and PPF after a year of treatment, according to data from two ...

The number of women dying during or soon after pregnancy in the UK is higher today than 10 years ago,1 with shocking reports of avoidable deaths, as articulated by The Lancet.2 ...

At least twice as many patients on the approved spesolimab dose maintain improvement in skin symptoms and quality of life ...

With a market cap of $681.8 billion, Eli Lilly and Company (LLY) is a leading global pharmaceutical company focused on ...

"We're thrilled to welcome Gagandeep Singh Bedi, his rare combination of corporate leadership and deep engagement with the ...

A new study is the first phase 3 to show meaningful improvement in both progression-free and overall survival with first-line ...

But for Ozzie and his wife Andreia, it’s about more than puppy paparazzi. “It’s special because I always grew up having dogs, ...

The BioMed X Institute has launched a new global call for research proposals in collaboration with Boehringer Ingelheim.

The new data from PureTech come after the company reported successful results from the phase 2b Elevate study in December ...

Two doses of 52-week nerandomilast, a phosphodiesterase 4B inhibitor, lowered FVC decline vs. placebo in patients with ...